Wednesday, February 4, 2026 at 11:31 AM
Novartis forecasts low single-digit sales growth and a decline in core operating income due to significant patent expiries, impacting profitability amid strong underlying earnings growth.
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Prices for GLP-1s are falling fast, forcing companies to adapt.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in 2030 was growing.
Data sourced from public RSS feeds and News APIs.
